CR20220175A - Combinación farmacéutica de inhibidores de PRMT5 - Google Patents

Combinación farmacéutica de inhibidores de PRMT5

Info

Publication number
CR20220175A
CR20220175A CR20220175A CR20220175A CR20220175A CR 20220175 A CR20220175 A CR 20220175A CR 20220175 A CR20220175 A CR 20220175A CR 20220175 A CR20220175 A CR 20220175A CR 20220175 A CR20220175 A CR 20220175A
Authority
CR
Costa Rica
Prior art keywords
inhibitor
pharmaceutical combination
kras
prmt5
prmt5 inhibitors
Prior art date
Application number
CR20220175A
Other languages
English (en)
Inventor
Mandar Ramesh Bhonde
Rajender Kumar Kamboj
Venkata P Palle
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of CR20220175A publication Critical patent/CR20220175A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente divulgación se refiere a combinaciones farmacéuticas para tratar y/o prevenir el cáncer y métodos y usos de las mismas. Más particularmente, se proporcionan una combinación farmacéutica que comprende un inhibidor de PRMT5 y un modulador de la actividad celular seleccionado de un inhibidor de EGFR, un inhibidor de KRAS, un inhibidor de KRAS-G12C, un inhibidor de MEK, un inhibidor de Bcl-2, un inhibidor de SOS1, un inhibidor de PARP, un inhibidor de RAF, un inhibidor de ERK, un inhibidor de CDK4/6, un inhibidor de MALT1, un inhibidor de BTK, un inhibidor de MAT2A, un inhibidor de PI3K, un inhibidor de AKT, un inhibidor de FGFR, un inhibidor de PRMT de tipo I, un agonista de STING o un inhibidor/modulador del punto de control inmunitario.
CR20220175A 2019-10-22 2020-10-22 Combinación farmacéutica de inhibidores de PRMT5 CR20220175A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921042899 2019-10-22
PCT/IB2020/059921 WO2021079302A1 (en) 2019-10-22 2020-10-22 Pharmaceutical combination of prmt5 inhibitors

Publications (1)

Publication Number Publication Date
CR20220175A true CR20220175A (es) 2022-06-21

Family

ID=73198360

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220175A CR20220175A (es) 2019-10-22 2020-10-22 Combinación farmacéutica de inhibidores de PRMT5

Country Status (16)

Country Link
US (1) US20220395508A1 (es)
EP (1) EP4048270A1 (es)
JP (1) JP2023504230A (es)
KR (1) KR20220086628A (es)
CN (1) CN114599361A (es)
AU (1) AU2020371295A1 (es)
BR (1) BR112022007808A2 (es)
CA (1) CA3156135A1 (es)
CO (1) CO2022005053A2 (es)
CR (1) CR20220175A (es)
EC (1) ECSP22032209A (es)
IL (1) IL292229A (es)
MX (1) MX2022004917A (es)
PE (1) PE20221154A1 (es)
WO (1) WO2021079302A1 (es)
ZA (1) ZA202203770B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024513494A (ja) * 2021-04-08 2024-03-25 ミラティ セラピューティクス、インコーポレイテッド がんの治療のためのｐｒｍｔ５阻害剤を使用する併用療法
AU2022253455A1 (en) * 2021-04-08 2023-11-02 Mirati Therapeutics, Inc. Combination therapies using prmt5 inhibitors for the treatment of cancer
WO2023004308A1 (en) * 2021-07-20 2023-01-26 Inspirna, Inc. Compositions and methods for inhibiting creatine transport as a treatment for cancer
TW202321246A (zh) * 2021-07-20 2023-06-01 大陸商上海齊魯製藥研究中心有限公司 Prmt5抑制劑
WO2023131305A1 (zh) * 2022-01-06 2023-07-13 江苏先声药业有限公司 Prmt5抑制剂和抗癌治疗剂的组合
CN116655638B (zh) * 2022-05-12 2024-01-26 上海齐鲁制药研究中心有限公司 氘代prmt5抑制剂
CN116211869B (zh) * 2022-12-07 2023-08-01 浙江省肿瘤医院 含dna损伤修复抑制剂的药物混合物及混合方法、用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9044432B2 (en) 2009-12-22 2015-06-02 Ohio State Innovation Foundation Compositions and methods for cancer detection and treatment
GB0922332D0 (en) 2009-12-22 2010-02-03 Isis Innovation Method of treatment and screening method
CA2894130A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
JP2016505000A (ja) 2012-12-21 2016-02-18 エピザイム，インコーポレイティド Ｐｒｍｔ５阻害剤およびその使用
WO2014100716A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
JP2016505597A (ja) 2012-12-21 2016-02-25 エピザイム，インコーポレイティド Ｐｒｍｔ５阻害剤およびその使用
JP6678455B2 (ja) 2012-12-21 2020-04-08 エピザイム，インコーポレイティド Ｐｒｍｔ５阻害剤およびその使用
GB201302927D0 (en) 2013-02-20 2013-04-03 Cancer Therapeutics Crc Pty Ltd Compounds
WO2014145214A2 (en) 2013-03-15 2014-09-18 Ohio State Innovation Foundation Inhibitors of prmt5 and methods of their use
WO2015198229A1 (en) 2014-06-25 2015-12-30 Glaxosmithkline Intellectual Property Development Limited Crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide
WO2015200680A2 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
WO2015200677A2 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
EP3177288A4 (en) 2014-08-04 2018-04-04 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US10005792B2 (en) 2014-09-03 2018-06-26 Ctxt Pty. Ltd. Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors
GB201415573D0 (en) 2014-09-03 2014-10-15 Cancer Therapeutics Crc Pty Ltd Compounds
US10494376B2 (en) 2014-09-03 2019-12-03 Ctxt Pty. Ltd. Tetrahydroisoquinoline derived PRMT5-inhibitors
WO2016038550A1 (en) 2014-09-11 2016-03-17 Novartis Ag Inhibition of prmt5 to treat mtap-deficiency-related diseases
WO2016089883A1 (en) * 2014-12-01 2016-06-09 Novartis Ag Compositions and methods for diagnosis and treatment of prostate cancer
AU2016225133B2 (en) 2015-02-24 2018-11-29 Pfizer Inc. Substituted nucleoside derivatives useful as anticancer agents
US20180271891A1 (en) 2015-03-11 2018-09-27 The Broad Institute Inc. Selective treatment of prmt5 dependent cancer
AR104326A1 (es) 2015-05-04 2017-07-12 Lilly Co Eli Compuestos nucleósidos 5-sustituidos
TWI791251B (zh) * 2015-08-26 2023-02-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物
JP7219218B2 (ja) * 2016-12-22 2023-02-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規のベンジルアミノ置換キナゾリンおよびｓｏｓ１阻害剤としての誘導体
EA201990851A1 (ru) * 2017-02-24 2019-09-30 Янссен Фармацевтика Нв Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5
BR112020002736A2 (pt) * 2017-08-09 2020-07-28 Prelude Therapeutics, Incorporated inibidores seletivos da proteína arginina metiltransferase 5 (prmt5)
KR20200051684A (ko) * 2017-09-07 2020-05-13 레볼루션 메디슨즈, 인크. 암 치료를 위한 shp2 억제제 조성물 및 방법
HRP20221207T1 (hr) * 2017-12-13 2022-12-09 Lupin Limited Supstituirani biciklički heterociklički spojevi kao inhibitori prmt5

Also Published As

Publication number Publication date
WO2021079302A1 (en) 2021-04-29
JP2023504230A (ja) 2023-02-02
MX2022004917A (es) 2022-08-04
CO2022005053A2 (es) 2022-04-29
BR112022007808A2 (pt) 2022-07-05
ZA202203770B (en) 2022-12-21
KR20220086628A (ko) 2022-06-23
EP4048270A1 (en) 2022-08-31
ECSP22032209A (es) 2022-05-31
CN114599361A (zh) 2022-06-07
CA3156135A1 (en) 2021-04-29
US20220395508A1 (en) 2022-12-15
PE20221154A1 (es) 2022-07-18
IL292229A (en) 2022-06-01
AU2020371295A1 (en) 2022-04-28

Similar Documents

Publication Publication Date Title
MX2022004917A (es) Combinación farmacéutica de inhibidores de prmt5.
AU2017382297A8 (en) Phosphodiesterase inhibitors and methods of microbial treatment
BR112018073328A2 (pt) combinação, composição farmacêutica, kit, método para tratamento de câncer, método para a redução de um nível de células, método para reduzir o nível de células, método para aumentar a atividade, método para aumentar a citotoxicidade
MX2018001351A (es) Inhibidores de los puntos de control inmunitarios para su uso en el tratamiento del cancer hematologico.
MX2019001125A (es) Inhibidores de cinasa macrociclica.
PH12017501155B1 (en) Thieno [2,3-c] pyrrol-4-one derivatives as erk inhibitors
WO2007057457A3 (en) Neuroendocrine tumor treatment using mtor inhibitors
PH12014501122A1 (en) Methods of treatment using an antibody against interferon gamma
ATE386034T1 (de) Pyrazoloisoquinolinenderivaten als kinase inhibitoren
SG10201909199PA (en) Method for treating cancer
MX346379B (es) Combinacion que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclina (cdk4/6) y un inhibidor de mtor para tratar cancer.
ATE421512T1 (de) Inhibitoren von mitotischem kinesin
NZ721280A (en) Pharmaceutical compositions and methods for treating cancer
BRPI0410331A (pt) método para tratar doença de disco degenerativa
MX2021016049A (es) Metodos de uso de inhibidores de rad51 para el tratamiento de cancer de pancreas.
MY195580A (en) Pyrimidopyrimidinones Useful as Wee-1 Kinase Inhibitors
ATE437653T1 (de) Verfahren zur behandlung von erkrankungen mit hsp90-hemmenden mitteln in kombination mit antimitotika
WO2015095838A3 (en) Cancer treatments using combinations of mek type i and erk inhibitors
MX2022008208A (es) Terapia de combinación que comprende inhibidores de a2a/a2b y proteína de muerte programada 1 /ligando de muerte programada 1 (pd-1/pdl1).
MX2019005450A (es) Composiciones y metodos farmaceuticos.
MX2021011524A (es) Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos.
BR112017018198A2 (pt) inibição da atividade de olig2
ZA201901367B (en) Inhibition of olig2 activity
EA201101639A1 (ru) Ингибиторы митохондриальной активности клеток, инициирующих рак, и их применение
MX2022010860A (es) Terapia combinada que comprende inhibidores de axl/mer y pd-1/pd-l1.